Expert Answer
Does BPC-157 actually work? What the evidence shows
Quick Answer
Honest answer: nobody really knows. BPC-157 shows promise for tissue repair in animal models, but there are essentially zero human randomized trials — Attia tried it himself and felt nothing, and Patrick flags the lack of human data. It is also FDA Category-2 restricted and widely banned in sport. Promising mechanism, anecdote-level evidence.
Moderate Consensus
on Peptides overall
What Researchers Say
Explains BPC-157's tissue-repair mechanism (angiogenesis) from animal models but stresses human clinical data is sparse — and warns its VEGF effect means it shouldn't be used continuously.
Tried BPC-157 personally and noticed no effect; calls this the "wild west" of medicine where the evidence is largely anecdotal, unlike proven interventions.
Flags the lack of substantial human data and the real risk of poor-quality sourcing — advises extreme caution rather than endorsement.
Platforms clinicians (Dr. Edwin Lee) who use the "Wolverine peptide" for muscle, tendon, and joint healing — though the cited evidence is clinician experience plus animal studies.
Detailed Answer
BPC-157 ("body protection compound") is the most-hyped recovery peptide on the internet, and the honest evidence picture is much thinner than the marketing suggests.
The case for it: in animal models, BPC-157 promotes angiogenesis (new blood-vessel growth) and cell migration that speed healing of gut, tendon, ligament, and nerve tissue. Huberman explains this mechanism, and Hyman's guest Dr. Edwin Lee — who calls it the "Wolverine peptide" — uses it clinically for muscle, tendon, and joint recovery. Dr. Craig Koniver (via Huberman) pairs it with PRP for ligament and tendon work.
The case against over-believing it: there are essentially no human randomized controlled trials. The human evidence is a small retrospective series and clinician anecdote — Huberman is explicit that "human clinical data remains sparse." Attia is blunter: he tried BPC-157 himself and noticed nothing, and files it under the "wild west" of unproven molecules. Patrick flags both the missing human data and the sourcing-quality problem. There is also a real safety caveat: because BPC-157 upregulates VEGF (the same pathway tumors use to build blood supply), Attia and Huberman both warn against continuous or preventative use due to a theoretical risk of accelerating an existing cancer.
Bottom line: a genuinely interesting mechanism with real animal data, near-zero human trials, a meaningful theoretical risk, FDA Category-2 restrictions, and a contamination-prone gray market (see "Are peptides safe?"). If you use it at all, the experts' position is: physician-supervised, quality-sourced, time-limited around a specific injury — not an open-ended self-experiment.
Related Questions
Are there human studies on BPC-157?
Essentially none of randomized-trial quality. The evidence is animal models plus small case series and clinician anecdote — Huberman notes human data is "sparse," Attia calls it anecdotal.
Is BPC-157 safe?
Unknown long-term. It upregulates VEGF, so Huberman and Attia caution against continuous or preventative use due to a theoretical tumor-growth risk. Sourcing (contamination) is a separate risk.
Is BPC-157 legal / allowed in sport?
The FDA moved it to "Category 2," restricting compounding-pharmacy production, and it is widely banned in competitive sport. Most supply is now gray-market "research only."
More Questions About Peptides
Get the exact protocol for Peptides
This page covers what researchers agree on. Pro gives you the specific dosages, timing schedules, and interaction warnings they each recommend — with video citations you can verify.
- Expert-by-expert breakdowns on any topic
- Chat with 1000+ hours of research data
- Video citations with timestamps you can check
Cancel anytime
Full Peptides Consensus Report
See what all the experts agree and disagree on